U.S. health regulator rebukes Novartis for advertising

 The Basel-based pharmaceutical company Novartis has been warned by the US Food and Drug Administration (FDA) for allegedly misleading advertising for the Alzheimer's drug Exelon. According to a letter from the FDA published on Tuesday, an advertising leaflet suggests that the drug is safer or more effective than proven, according to the SDA. The authority has asked Novartis to stop using the sales prospectus of the sales force. The pharmaceutical company now wants to discuss the case with the FDA and review the advertising material, a company spokesperson told SDA. If necessary, the sales prospectus will be adapted. According to the Basel-based company, such warnings from the FDA occur time and again in the pharmaceutical industry.